Aquestive Therapeutics, Inc. Price-FCF Ratio
The price-to-free-cash-flow (P/FCF) ratio tells you how many dollars investors pay for each dollar of cash a company generates after paying for its capital spending. It is market capitalization divided by free cash flow over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher ratio means investors are paying more for each dollar of free cash flow; a negative ratio means the company spent more cash than it generated over those quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.
- Aquestive Therapeutics, Inc. price-fcf ratio for the quarter ending 2026-06-30 was -11.36, a change of -4.79 year-over-year.
- Aquestive Therapeutics, Inc. price-fcf ratio for the quarter ending 2026-03-31 was -11.65, a change of -5.78 year-over-year.
- Aquestive Therapeutics, Inc. price-fcf ratio for the quarter ending 2025-12-31 was -14.85, a change of -5.79 year-over-year.
- Aquestive Therapeutics, Inc. price-fcf ratio for the quarter ending 2025-09-30 was -13.33, a change of -0.12 year-over-year.
- Aquestive Therapeutics, Inc. price-fcf ratio for fiscal 2026 was -11.36.
- Aquestive Therapeutics, Inc. price-fcf ratio for fiscal 2025 was -14.85, a change of -5.79 from fiscal 2024.
- Aquestive Therapeutics, Inc. price-fcf ratio for fiscal 2024 was -9.06, a change of 9.71 from fiscal 2023.
- Aquestive Therapeutics, Inc. price-fcf ratio for fiscal 2023 was -18.77, a change of -14.21 from fiscal 2022.
- Available history
- 2018-09-30 to 2026-06-30
- Data captured
Historical Price-FCF Ratio
Annual Price-FCF Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |